Cancer immunotherapy comes of age and looks for maturity
As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future.
Saved in:
Main Authors: | Amanda Finck, Saar I. Gill, Carl H. June |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/b79c612e2f44404b8f5683d98f5ab4b9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
by: Christopher Sloas, et al.
Published: (2021) -
Single cell transcriptomics comes of age
by: Sarah Aldridge, et al.
Published: (2020) -
Bacterial Epigenomics: Coming of Age
by: Pedro H. Oliveira
Published: (2021) -
Euroquant at 21: “coming of age”?
by: David Unwin
Published: (1999) -
Correction for Oliveira, “Bacterial Epigenomics: Coming of Age”
by: Pedro H. Oliveira
Published: (2021)